— Know what they know.
Not Investment Advice
Also trades as: PFE.DE (XETRA) · $vol 1M · PFE.NE (NEO) · $vol 1M · PFE.F (FSX) · $vol 0M · PFE.BA (BUE) · $vol 0M

PFE NYSE

Pfizer Inc.
1W: +0.8% 1M: -3.2% 3M: -2.6% YTD: +4.8% 1Y: +14.2% 3Y: -18.3% 5Y: -19.0%
$25.90
-0.05 (-0.19%)
 
Weekly Expected Move ±2.4%
$24 $25 $25 $26 $27
NYSE · Healthcare · Drug Manufacturers - General · Alpha Radar Neutral · Power 51 · $147.6B mcap · 5.69B float · 0.665% daily turnover · Short 39% of daily vol

Cash Flow Trends

Operating Cash Flow
$11.7B -8.2% ▼
5Y CAGR: -4.1%
Capital Expenditures
$2.6B +9.6% ▲
5Y CAGR: -1.2%
Free Cash Flow
$9.1B -7.7% ▼
5Y CAGR: -4.8%
Dividends Paid
$9.8B -2.7% ▼
Buybacks
$0 +0.0% ▲
Net Change in Cash
$99M +105.5% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$22.5B$31.4B$2.2B$8.1B$7.7B
Depreciation & Amort.$5.2B$5.1B$6.3B$7.0B$6.6B
Stock-Based Comp.$1.2B$872M$525M$877M$0
Change in Working Capital$12.8B-$4.5B-$2.2B-$3.1B-$5.4B
Other Non-Cash Items-$4.8B$150M$5.3B$2.0B$4.9B
Operating Cash Flow$32.6B$29.3B$8.7B$12.7B$11.7B
— Investing Activities —
Capital Expenditures-$2.7B-$3.2B-$3.9B-$2.9B-$2.6B
Acquisitions (Net)-$12M-$23.0B-$43.4B$7.0B-$6.9B
Investment Purchases-$47.6B-$38.8B-$31.2B-$10.3B-$14.7B
Investment Sales$28.1B$45.5B$46.4B$8.8B$22.7B
Other Investing-$306M$3.8B-$180M$0$165M
Investing Cash Flow-$22.5B-$15.8B-$32.3B$2.7B-$1.4B
— Financing Activities —
Net Debt Issuance-$1.1B-$3.5B$35.9B-$7.2B-$74M
Stock Repurchased$0-$2.0B$0$0$0
Dividends Paid-$8.7B-$9.0B-$9.2B-$9.5B-$9.8B
Other Financing$16M-$335M-$632M-$469M-$459M
Financing Cash Flow-$9.8B-$14.8B$26.1B-$17.1B-$10.3B
Net Change in Cash$158M-$1.5B$2.4B-$1.8B$99M
Cash End of Period$2.0B$468M$2.9B$1.1B$1.1B
Free Cash Flow$29.9B$26.0B$4.8B$9.8B$9.1B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms